5 Key Takeaways

• 1

  Nirmatrelvir–ritonavir treatment for up to 25 days did not improve symptoms of cognitive dysfunction, autonomic dysfunction, or exercise intolerance in long COVID patients.

• 2

  The RECOVER-VITAL trial involved 964 patients with persistent symptoms for at least 12 weeks post-SARS-CoV-2 infection, with a median age of 49 years.

• 3

  No statistically significant improvement was observed in primary outcomes for any of the three symptom phenotypes among patients receiving active treatment.

• 4

  Subgroup analyses showed no differential treatment effects based on vaccination status, race, ethnicity, sex, or prior treatment during initial infection.

• 5

  The trial did not establish the effect of longer antiviral treatment durations or the impact of viral persistence on long COVID symptomatology.